ストックスクリーナーアプリを入手
7.48
4.10%
-0.32
アフターアワーズ：
7.47
-0.01
-0.13%
前日終値:
$7.80
開ける：
$7.93
24時間の取引高:
58,262
Relative Volume:
5.67
時価総額：
$30.26M
収益：
$8.30M
当期純損益:
$-52.26M
株価収益率:
0.1901
EPS:
39.3379
ネットキャッシュフロー:
$-17.14M
1週間 パフォーマンス:
-0.27%
1か月 パフォーマンス:
-17.53%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$7.32
$7.97
1週間の範囲:
$7.32
$8.63
52週間の値動き範囲:
$7.32
$9.58
Kyntra Bio Inc Stock (KYNB) Company Profile
Compare KYNB vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KYNB
Kyntra Bio Inc
|
7.48 | 31.55M | 8.30M | -52.26M | -17.14M | 39.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Kyntra Bio Inc Stock (KYNB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-08-08 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-06-26 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-06-26 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2023-06-26 | ダウングレード | Stifel | Buy → Hold |
| 2023-06-26 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-06-02 | アップグレード | Stifel | Hold → Buy |
| 2023-01-31 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2023-01-26 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-01-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-09-22 | ダウングレード | Goldman | Neutral → Sell |
| 2021-08-20 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2021-07-16 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-07-16 | ダウングレード | Stifel | Buy → Hold |
| 2021-04-07 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-04-07 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-03-31 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-03-02 | ダウングレード | Jefferies | Buy → Hold |
| 2021-02-01 | 開始されました | H.C. Wainwright | Buy |
| 2020-10-26 | 開始されました | Raymond James | Underperform |
| 2020-07-10 | 再開されました | Stifel | Buy |
すべてを表示
Kyntra Bio Inc (KYNB) 最新ニュース
Kyntra Bio Charts a New Course in Oncology - AD HOC NEWS
FibroGen rebrands as Kyntra Bio, refocuses on oncology - TipRanks
FibroGen announces rebrand as Kyntra Bio - TipRanks
FibroGen stock rises after announcing rebrand to Kyntra Bio - Investing.com
FibroGen (FGEN) Transforms into Kyntra Bio with a New Focus - GuruFocus
FibroGen rebrands as Kyntra Bio with new Nasdaq ticker KYNB - Investing.com
FibroGen, Inc. Rebrands to Kyntra Bio, Targeting Oncology and Rare Disease Therapeutics with New Nasdaq Trading Symbol "KYNB" - Quiver Quantitative
FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum - GlobeNewswire
Roxadustat Granted Orphan Drug Designation for the - GlobeNewswire
FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit - GlobeNewswire
FibroGen Sells China Unit To AstraZeneca And Refocuses - Finimize
FibroGen (NASDAQ: FGEN) sets Q3 results; 5:00 PM ET conference call Monday - Stock Titan
FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million - GlobeNewswire
Major Regulatory Win: FibroGen's $815M China Business Sale to AstraZeneca Gets Green Light from Regulators - Stock Titan
FGENFibrogen Inc Latest Stock News & Market Updates - Stock Titan
FibroGen Announces 1-for-25 Reverse Stock Split - GlobeNewswire
FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors - marketscreener.com
FibroGen: Q1 Earnings Snapshot - marketscreener.com
FGEN Stock Price, News & Analysis - Stock Titan
Investors Don't See Light At End Of FibroGen, Inc.'s (NASDAQ:FGEN) Tunnel And Push Stock Down 26% - simplywall.st
FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference - marketscreener.com
FibroGen: Q4 Earnings Snapshot - marketscreener.com
FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results - marketscreener.com
FibroGen to Sell China Unit to AstraZeneca for $160 Million - marketscreener.com
FibroGen, Inc. Appoints David DeLucia as Chief Financial Officer - marketscreener.com
FibroGen: Q3 Earnings Snapshot - marketscreener.com
FibroGen to Report Third Quarter 2024 Financial Results - marketscreener.com
FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference - marketscreener.com
FibroGen: Q2 Earnings Snapshot - marketscreener.com
FibroGen to Report Second Quarter 2024 Financial Results - marketscreener.com
FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference - marketscreener.com
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference - marketscreener.com
FibroGen regains rights to anemia drug from AstraZeneca - marketscreener.com
FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results - marketscreener.com
Fibrogen, Inc. Announces Chief Executive Officer Changes - marketscreener.com
Down 80% in 1 Day, Is There Any Hope for FibroGen Stock? - The Motley Fool
Big Pharma Companies Have Higher US FDA Approval Percentage Than Everybody Else - Citeline News & Insights
Meet Ananth Narayanan, Ex-Myntra CEO, Mensa Brands founder: Know about his journey, education & family - The Financial Express
FibroGen: Despite Some Progress, Roxadustat's Data Disaster Still Haunts It (NASDAQ:FGEN) - Seeking Alpha
Goldman Sachs Adjusts Price Target on FibroGen to $9 From $8, Maintains Sell Rating - marketscreener.com
Time To Worry? Analysts Are Downgrading Their FibroGen, Inc. (NASDAQ:FGEN) Outlook - simplywall.st
FibroGen to Present at H.C. Wainwright Bioconnect Virtual Conference - marketscreener.com
What's Next for FibroGen After an FDA Vote Against Its Anemia Drug? - The Motley Fool
Here's Why FibroGen Stock Is Plunging Today - The Motley Fool
FibroGen, Inc. Appoints John Hunter as Chief Scientific Officer - marketscreener.com
Why FibroGen Stock Is Crashing Today - The Motley Fool
FibroGen to Present at Upcoming Investor Conferences - GlobeNewswire
Cue Biopharma (CUE) Stock Price, Quote, News & History - Benzinga
FibroGen, Inc. Appoints Thane Wettig as Chief Commercial Officer - marketscreener.com
FibroGen, Inc. Announces Resignation of James Schoeneck as Interim President - marketscreener.com
FibroGen Appoints Enrique Conterno as Its New CEO - The Motley Fool
Kyntra Bio Inc (KYNB) 財務データ
収益
当期純利益
現金流量
EPS
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):